Skip to content
← Full study record

NCT05546476 · MORE INFO

Limitations, agreements, and source contact

Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 · Source last updated 2026-06-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrials.gov_Inquiries@pfizer.com
organization
Pfizer Inc.
phone
1-800-718-1021
title
Pfizer ClinicalTrials.gov Call Center
Complete source fields
certain Agreement
other Details
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ClinicalTrials.gov_Inquiries@pfizer.com
organization
Pfizer Inc.
phone
1-800-718-1021
title
Pfizer ClinicalTrials.gov Call Center

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice